Aflibercept - Retinopathy of prematurity

You are here : Home > Formulary Search > Aflibercept - Retinopathy of prematurity

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative

Formulations :

Not Specified

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

NFD2

Restrictions / Comments :

Important

Not assessed for inclusion on the formulary. Contact pharmacy team for advice on making an application.

Documentation

No records returned.

PAD Profile

ChemicalSubstance :

Aflibercept

Indication :

Retinopathy of prematurity

Group Name :

Keywords :

ROP

Brand Names Include :

Eylea

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Aflibercept is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Retinopathy of prematurity.

No records returned.

Committee Recommendations (1)

06 Apr 23 - Not Set

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net if they wish to make a submission.